Section Arrow
AYTU.NASDAQ
- Aytu BioPharma
Quotes are at least 15-min delayed:2024/11/10 17:34 EST
Last
 1.64
-0.1752 (-9.65%)
Day High 
1.9328 
Prev. Close
1.8152 
1-M High
2.382 
Volume 
68.08K 
Bid
1.6
Ask
1.84
Day Low
1.6 
Open
1.7 
1-M Low
1.77 
Market Cap 
10.84M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.95 
20-SMA 2.09 
50-SMA 2.3 
52-W High 3.45 
52-W Low 1.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.86/0.11
Enterprise Value
21.72M
Balance Sheet
Book Value Per Share
4.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
81.00M
Operating Revenue Per Share
17.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.49-0.06-3.87%-- 
ESPREsperion Therapeutics2.275+0.165+7.82%-- 
VTRSViatris12.96-0.22-1.67%227.2PE
HLNHaleon plc9.61+0.01+0.10%31.1PE
CGCCanopy Growth Corp4.24-0.31-6.81%-- 
Quotes are at least 15-min delayed:2024/11/10 17:34 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidityand a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.